Histidine analogues as potential novel antirheumatic agents

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Copper chelation and superoxide radical scavenging are potential therapeutic strategies for inflammatory diseases like rheumatoid arthritis.
• D-penicillamine, an antirheumatic drug, acts via a putative mechanism involving copper chelation and radical scavenging.
• Novel compounds are needed to explore alternative or improved therapeutic approaches.

Purpose of the Study:

• To evaluate the copper-chelating avidity of new histidine analogues.
• To assess the capacity of these copper chelates to catalyze the dismutation of the superoxide radical.
• To identify structure-activity relationships for potential antirheumatic agents.

Main Methods:

• Development and application of a novel in vitro test system.
• Assessment of copper chelation avidity for various histidine analogues.
• Measurement of the catalytic activity of histidine-copper chelates in superoxide radical dismutation.

Main Results:

• Several novel histidine analogues exhibited significant copper-chelating avidity.
• The resulting copper chelates demonstrated catalytic activity in superoxide radical dismutation.
• Isohistidine (alpha-amino-2-imidazolepropionic acid) and its derivatives were identified as particularly active compounds.
• Structure-activity relationships were established within the series of tested histidine analogues.

Conclusions:

• Novel histidine analogues possess the requisite properties for potential antirheumatic drug development.
• Isohistidine derivatives represent a promising class of compounds for further investigation as antirheumatic agents.
• The developed in vitro test is a valuable tool for screening potential antirheumatic agents based on copper chelation and radical scavenging.